Oarsman Capital Inc. Grows Position in Zoetis Inc. $ZTS

Oarsman Capital Inc. lifted its position in Zoetis Inc. (NYSE:ZTS) by 8.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,071 shares of the company’s stock after purchasing an additional 158 shares during the quarter. Oarsman Capital Inc.’s holdings in Zoetis were worth $323,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Nova Wealth Management Inc. purchased a new stake in shares of Zoetis in the first quarter valued at about $25,000. 1248 Management LLC purchased a new stake in shares of Zoetis in the first quarter valued at about $27,000. Saudi Central Bank purchased a new stake in shares of Zoetis in the first quarter valued at about $29,000. REAP Financial Group LLC grew its holdings in shares of Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after purchasing an additional 131 shares during the period. Finally, Cornerstone Planning Group LLC grew its holdings in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after purchasing an additional 88 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on ZTS shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. UBS Group lowered their target price on shares of Zoetis from $165.00 to $158.00 and set a “neutral” rating for the company in a research note on Monday, October 20th. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Argus reaffirmed a “buy” rating and set a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Finally, Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $195.00.

Zoetis Stock Down 1.0%

Shares of ZTS opened at $143.97 on Thursday. The stock has a market capitalization of $63.80 billion, a PE ratio of 24.78, a P/E/G ratio of 2.34 and a beta of 0.90. Zoetis Inc. has a 1 year low of $139.34 and a 1 year high of $183.81. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The company’s 50-day simple moving average is $147.63 and its 200-day simple moving average is $153.48.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business’s quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is 34.42%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.